Important Activities

Scientific Program

Project Matchmaking

Keynote Forum

Stream 7

Stream 8

Stream 9

Stream 10

Plenary Talk

Stream 11

Stream 12

Stream 13

Stream 14

Stream 12 From Disease Basic Science to Clinical Application

Stream 1201: Cancers/Tumors - Part I
Time: 13:30-17:10, Nov 16, 2019(Saturday)
Place: FUNCTION ROOM 1, 3^rd Floor, HOTEL UNIC

Chair: Dr. Iduna Fichtner, COO, EPO Experimental Pharmacology and Oncology GmbH, Germany

Time

Face On

Speeches and Speakers

13:30-13:35

Chair's Introduction

13:35-14:00

Title: Prospects and Limitations of Patient-derived Xenografts (PDX) in Translational Cancer Research
Dr. Iduna Fichtner, COO, EPO Experimental Pharmacology and Oncology GmbH, Germany

14:00-14:25

Title: Preclinical Verification of the Efficacy of Targeting Peptides Linked Lliposomal Nanoparticles for Therapy of Hepatocellular and Nasopharyngeal Carcinomas and Breast Cancer
Dr. Chin-Tarng Lin, Professor Emeritus of Pathology, National Taiwan University Hospital, Taiwan

14:25-14:50

Title: Development of a Human Cancer Vaccine to a Unique Adenocarcinoma Target
Dr. James (Jim) Radosevich, Chief Scientific Officer, LabyRx Immunologic Therapeutics Limited, USA

14:50-15:15

Title:  Novel Radiation Mitigators and Anticancer Drugs Yel002 and CJ010
Dr. Robert H. Schiestl, Professor, UCLA Schools of Medicine and Public Health, USA

15:15-15:30

Coffee Break

15:30-15:55

15:55-16:20

Title: Novel Therapeutic Drug Combinations with CDK4/6 Inhibitors in Breast Cancer
Dr. Uzma Saddia Asghar, Medical Oncologist, NIHR Clinical Research Facility, University College London Hospital (UCLH), UK

16:20-16:45

Title: Application of PDX Cancer Models in Co-clinical Trails and Personalized/Precision Medicine
Dr. Hongwei Cheng, Adjunct Professor, Living Tumor Laboratory, BC Cancer Agency/Vancouver Prostate Centre, Canada

16:45-17:10

Stream 1202: CNS and Neurodegenerative Disorders
Time: 08:30-10:35, Nov 17, 2019(Sunday)
Place: FUNCTION ROOM 4, 3^rd Floor, HOTEL UNIC

Chair: Dr. Arieh S Solomon, Associate Professor, Tel Aviv University, Israel

Time

Face On

Speeches and Speakers

08:30-08:35

Chair's Introduction

08:35-08:55

Title: Delivery of Copper-chelating Trientine (TETA) to the Central Nervous System
Dr. Gert Fricker, Director, Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls University, Germany

Title: First-in-Human Study of ATB200/AT2221 in Patients With Pompe Disease: 24-Month Functional Assessment Results From the ATB200-02 Trial
Dr. Sue Xue Ming, Professor, Rutgers New Jersey Medical School, USA

09:15-09:35

Title: Prolonged Inhibition of Semaphorin3A Pathway via Biodegradable Iimplant towards a Better Therapy for Visual Sensory Impairments
Dr. Arieh S Solomon, Associate Professor, Tel Aviv University, Israel

09:35-09:55

Title: Molecular imaging of the Synaptic Vesicle Protein SV2A, a New Biomarker for Alzheimer’s Disease and Other Neurodegenerative Disorders
Dr. Yiyun Henry Huang, Professor and Director of Chemistry and Co-Director of the PET Center, Yale University School of Medicine, USA

Title: Challenges Associated with Diagnosing and Managing Fetal Alcohol Spectrum Disorder (FASD)
Dr. Katarzyna Okulicz-Kozaryn, Head of the Department of Education, State Agency for Prevention of Alcohol Related Problems (PARPA), Poland

Stream 1203: Cancers/Tumors - Part Il
Time: 10:25-12:30, Nov 17, 2019(Sunday)
Place: FUNCTION ROOM 3, 3^rd Floor, HOTEL UNIC

Chair: Dr. Zaihui Zhang, CSO and VP R&D, Signalchem Lifesciences Corp., Canada

Time

Face On

Speeches and Speakers

10:25-10:30

Chair's Introduction

10:30-10:50

Title:  Replacing Digital Rectal Examination (DRE) and PSA (Prostate Specific Antigen) with A New Urine  NV-VPAC1 TM Test for Prostate Cancer
Dr. Jay T. Bishoff, Director, Intermountain Urological Institute; Clinical Professor of Surgery, University School of Medicine, USA

10:50-11:10

Title: SLC-391 – A Potent and Selective Axl Inhibitor for Cancer Therapy
Dr. Zaihui Zhang, CSO and VP R&D, Signalchem Lifesciences Corp., Canada

11:10-11:30

Title: A Second Generation TRK Kinase Inhibitor that Overcomes Acquired Resistance to First Generation Inhibitors in Patients with TRK-fusion Cancer
Dr. Yanchun Gong, Vice president, Jiangsu Vcare PharmaTech Co., Ltd, China

11:30-11:50

Title: Tumor Chemotherapy and the Inhibition of Drug Resistance Based on Structure-activity Relationship and Specific Tumor Energy Metabolism
Dr. Guohui Sun, Professor, Beijing University of Technology, China

Title: Cold Atmospheric Plasma Selectively Kills Cancer Stem Cells and Create Synergies with Atorvastatin
Dr. Xiaofeng Dai, Professor, Jiangnan University, China

Stream 1204: Clinical Research and Clinical Trials
Time: 08:30-10:15, Nov 17, 2019(Sunday)
Place: FUNCTION ROOM 3, 3^rd Floor, HOTEL UNIC

Chair: Dr. Alan A. Chalmers, Director, Pharma International, Switzerland

Time

Face On

Speeches and Speakers

08:30-08:35

Chair's Introduction

08:35-08:55

08:55-09:15

Title: Regulatory Requirements in China Concerning the Needs for Clinical Trials, the Usefulness of Multinational Trials, the Acceptance of Foreign Clinical Data – the Way Ahead into 2020 Including the Opportunities Arising from ICH in China
Dr. Alan A. Chalmers, Director, Pharma International, Switzerland

09:15-09:35

09:35-09:55

Title: Use of Pharmacometrics Experts, How Can it Save Companies Time and Money?
Dr. Aruna Dontabhaktuni, Founder and CEO, PharmaPro Consulting Inc., USA